mantle cell lymphoma

Brian T. Hill, MD, PhD, Co-Director of the Lymphoid Malignancies Program at Cleveland Clinic, joins the Cancer Advances Podcast to discuss advances in mantle cell lymphoma. Listen as Dr. Hill highlights current treatments and how promising strategies like BTK inhibitors and CAR T-cell therapy are being used. He also addresses challenges such as TP-53 mutations, discusses potential advancements, and emphasizes the importance of individualized treatment approaches.

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: 

• SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL 
• TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL 
• ZUMA-2: Brexucabtagene Autoleucel in R/R MCL 
• BRUIN: Pirtobrutinib for Previously Treated MCL 
• GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL 
• FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL 
• ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL 
• ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL 
• BRUIN: Pirtobrutinib for Previously Treated CLL

Presenters: 

Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Link to full program: 
https://bit.ly/3MNaUri

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:

• GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia 
• BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor)

Presenters:

Christopher R. Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center 
Houston, Texas

Kami Maddocks, MD
Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
• SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)
• MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLL
• BRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)
• BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator’s choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCL
• BRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCL

Presenters: 

Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to full program:
https://bit.ly/3OQ6634

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: 

• GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
• FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
• BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
• SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL

Presenters:

Othman Al-Sawaf, MD
Faculty of Medicine
University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne 
Düsseldorf, Germany
Visiting Scientist
The Francis Crick Institute
UCL Cancer Institute, University College London 
London, United Kingdom

Lydia Scarfò, MD
Laboratory of B-Cell Neoplasia, Division of Experimental Oncology
Strategic Research Program on CLL
Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele
Milano, Italy

Link to full program:
https://bit.ly/3OQ6634

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of: 

• The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL
• 3-year follow-up analysis from the CAPTIVATE fixed-duration cohort of first-line ibrutinib plus venetoclax for CLL/small lymphocytic lymphoma
• Phase I/II study of zilovertamab, an anti-ROR1 antibody, plus ibrutinib in MCL or CLL

Presenters:

Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri 

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

See full program:
https://bit.ly/3OQ6634

In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:

• Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCL
• Updated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCL
• Results from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLL
• Preliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapies

Presenters:

Tycel J. Phillips, MD 
Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation
Associate Professor of Medicine
University of Michigan 
Rogel Cancer Center 
Ann Arbor, Michigan

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate, Department of Medicine
Johns Hopkins University
Nurse Practitioner, Department of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Content supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/3yufCU4

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and  emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

• For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
• What is the optimal therapy for a patient with del(17p) CLL?
• When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
• What are best practices in the use of BTK inhibitors for patients with MCL?
• How can BTK inhibitor resistance occur?
• How might investigational noncovalent BTK inhibitors be used should they be approved?
• What are key adverse events with BTK inhibitors?

Presenters:

Jeff P. Sharman, MD (chair)
Medical Director
Hematology Research
US Oncology 
Willamette Valley Cancer Institute
Eugene, Oregon 

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Content based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5. 

Link to full program:
https://bit.ly/3NEpsYQ

In this episode, Julie M. Vose, MD, MBA;  Brad S. Kahl, MD; and  John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: 

• Follicular lymphoma
• Marginal zone lymphoma
• Mantle cell lymphoma
• Diffuse large B-cell lymphoma
• Posttransplant lymphoproliferative disorder

Presenters:

Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Link to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:
https://bit.ly/3tb47wU

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:

• BTK inhibitor selectivity
• BTK inhibitor adverse event profiles
• Ibrutinib intolerance
• Management of common adverse events

Presenter:

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:

• Rationale for inhibiting BTK
• MOA of BTK inhibitors
• Approved BTK inhibitors
• Recent clinical trial findings

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Presenter: 

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:

• Approved and Investigational Targeted Therapeutics for CLL  
• Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
• Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
• Treatment for Older Patients With Hodgkin Lymphoma

Presenters:

Jeremy S. Abramson, MD, MMSc
Associate Professor  
Department of Medicine  
Harvard Medical School  
Director, Center for Lymphoma  
Massachusetts General Hospital  
Boston, Massachusetts

Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.

Link to full program:
https://bit.ly/3tyQ9nG